Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S. Iaccarino

The Addition at Day 9 of Hd-MTX to the (Da)-Epoch Scheme With or Without Rituximab Is an Effective Regimen in Untreated Advanced Stage High Risk Lymphoma: A Feasibility Study

Hematological Oncology

English

Biostratigraphy of Miocene Deep Sea Sediments (Sites 372 and 375), With Special Reference to the Messinian/Pre-Messinian Interval

1978

English

Related publications

Immunochemotherapy With Obinutuzumab or Rituximab in Previously Untreated Follicular Lymphoma in the Randomised Phase Iii Gallium Study: Analysis by Chemotherapy Regimen

Hematological Oncology

English

High-Dose Methotrexate With or Without Rituximab in Newly Diagnosed Primary CNS Lymphoma

Neurology

2014

English

T(11;18)(q21;q21)-Positive Advanced-Stage MALT Lymphoma Associated With Monoclonal Gammopathy : Resistance to Rituximab or Rituximab-Containing Chemotherapy

Journal of clinical and experimental hematopathology : JCEH

Medicine

2008

English

Ebeacopp With or Without Rituximab in Interim-Pet-Positive Advanced-Stage Hodgkin Lymphoma: Updated Results of the International, Randomized Phase 3 GHSG Hd18 Trial

Hematological Oncology

English

Rituximab Plus Lenalidomide Is as Effective as Immunochemotherapy in the Eradication of Molecular Disease in Untreated Follicular Lymphoma: Relevance Lysa Ancillary Study

Hematological Oncology

English

Da-Epoch-R Versus R-Chop in High Risk DLBCL Patients: Analysis of the Czech Lymphoma Study Group (Clsg)

Hematological Oncology

English

Differences in Quality of Life Between Bendamustine-Rituximab and R-Chop/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Clinical Lymphoma, Myeloma and Leukemia

English

Correction To: White Matter Changes in Primary Central Nervous System Lymphoma Patients Treated With High-Dose Methotrexate With or Without Rituximab

Journal of Neuro-Oncology

English

The Glasgow Prognostic Score at Diagnosis Is an Independent Predictor of Survival in Advanced Stage Classical Hodgkin Lymphoma

British Journal of Haematology

Hematology

2018

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S. Iaccarino

The Addition at Day 9 of Hd-MTX to the (Da)-Epoch Scheme With or Without Rituximab Is an Effective Regimen in Untreated Advanced Stage High Risk Lymphoma: A Feasibility Study

Biostratigraphy of Miocene Deep Sea Sediments (Sites 372 and 375), With Special Reference to the Messinian/Pre-Messinian Interval

Related publications

Immunochemotherapy With Obinutuzumab or Rituximab in Previously Untreated Follicular Lymphoma in the Randomised Phase Iii Gallium Study: Analysis by Chemotherapy Regimen

High-Dose Methotrexate With or Without Rituximab in Newly Diagnosed Primary CNS Lymphoma

T(11;18)(q21;q21)-Positive Advanced-Stage MALT Lymphoma Associated With Monoclonal Gammopathy : Resistance to Rituximab or Rituximab-Containing Chemotherapy

Ebeacopp With or Without Rituximab in Interim-Pet-Positive Advanced-Stage Hodgkin Lymphoma: Updated Results of the International, Randomized Phase 3 GHSG Hd18 Trial

Rituximab Plus Lenalidomide Is as Effective as Immunochemotherapy in the Eradication of Molecular Disease in Untreated Follicular Lymphoma: Relevance Lysa Ancillary Study

Da-Epoch-R Versus R-Chop in High Risk DLBCL Patients: Analysis of the Czech Lymphoma Study Group (Clsg)

Differences in Quality of Life Between Bendamustine-Rituximab and R-Chop/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Correction To: White Matter Changes in Primary Central Nervous System Lymphoma Patients Treated With High-Dose Methotrexate With or Without Rituximab

The Glasgow Prognostic Score at Diagnosis Is an Independent Predictor of Survival in Advanced Stage Classical Hodgkin Lymphoma